MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma

Abstract

// Yanwei Zhang 1 , Keke Yu 2 , Song Hu 3 , Yuqing Lou 1 , Chunxing Liu 4 , Jianlin Xu 1 , Rong Li 1 , Xueyan Zhang 1 , Huimin Wang 1 , Baohui Han 1 1 Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China 2 Department of Biobank, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China 3 Department of Research Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China 4 Department of Laboratory Medicine, Huadong Sanatorium, Wuxi, Jiangsu Province, PR China Correspondence to: Baohui Han, email: [e-mail] Keywords: early stage lung adenocarcinoma, subcentimeter lung adenocarcinoma, inflammatory biomarkers Received: August 17, 2016     Accepted: October 05, 2016     Published: November 03, 2016 ABSTRACT Background : This prospective study was designed to investigate the association between ten circulating inflammatory biomarkers and the risk for early stage lung adenocarcinoma. Methods: All inflammatory biomarkers were measured in 228 patients with early stage (IA to IIB) lung adenocarcinoma and 228 age-, sex- and smoking-matched healthy controls by using the Luminex bead-based assay. Results: Only two biomarkers were significantly associated with the risk of early stage lung adenocarcinoma after the Bonferroni correction: the multivariate odd ratio (OR) (95% confidence interval or CI) was 0.29 (0.16-0.53) for MDC and 4.17 (2.23-7.79) for BLC for the comparison of patients in the 4 th quartile with the 1 st quartile (both P<0.0001). When analysis was restricted to never smokers (196 patients/196 controls), MDC and BLC were still significantly associated with the risk of early stage lung adenocarcinoma (OR, 95% CI, P: 0.37, 0.21-0.66, P<0.0001 for MDC and 2.78, 1.48-5.22, P =0.001 for BLC). Furthermore, elevated BLC was associated with a 2.90-fold (95% CI: 1.03-8.17, P=0.037) increased risk of subcentimeter lung adenocarcinoma, and there was an increasing trend for BLC with the progression of subcentimeter lung adenocarcinoma. Conclusion: Our findings demonstrated that MDC and BLC were independently associated with the significant risk of early stage lung adenocarcinoma, even in non-smokers and in stage IA patients. BLC was further identified to play a carcinogenic role in the progression of lung adenocarcinoma.